Show simple item record

dc.contributor.authorBalasegaram, Manica
dc.contributor.authorRitmeijer, Koert
dc.contributor.authorLima, Maria Angeles
dc.contributor.authorBurza, Sakib
dc.contributor.authorOrtiz Genovese, Gemma
dc.contributor.authorMilani, Barbara
dc.contributor.authorGaspani, Sara
dc.contributor.authorPotet, Julien
dc.contributor.authorChappuis, François
dc.date.accessioned2012-12-11T20:36:10Z
dc.date.available2012-12-11T20:36:10Z
dc.date.issued2012-12-11
dc.date.submitted2012-11
dc.identifier.citationLiposomal amphotericin B as a treatment for human leishmaniasis 2012, 17 (4):493 Expert Opinion on Emerging Drugsen_GB
dc.identifier.issn1472-8214
dc.identifier.issn1744-7623
dc.identifier.doi10.1517/14728214.2012.748036
dc.identifier.urihttp://hdl.handle.net/10144/255342
dc.language.isoenen
dc.publisherInformaen_GB
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.1517/14728214.2012.748036en_GB
dc.rightsArchived with thanks to Expert Opinion on Emerging Drugsen_GB
dc.subjectLeishmaniasisen_GB
dc.titleLiposomal amphotericin B as a treatment for human leishmaniasisen
dc.typeArticleen
dc.contributor.departmentDrugs for Neglected Diseases Initiative, Geneva, Switzerland;2 Médecins Sans Frontières, Operational Centre Amsterdam, Amsterdam, The Netherlands; Médecins Sans Frontières, Operational Centre Barcelona Athens, Barcelona, Spain; Médecins Sans Frontières, Access Campaign, Paris, France; Médecins Sans Frontières, Operational Centre Geneva, Geneva, Switzerland;Médecins Sans Frontières, Access Campaign, Geneva, Switzerland; University of Geneva, andGeneva University Hospitals, Division of International and Humanitarian Medicine, 6, rue Gabrielle-Perret-Gentil, 1211 Geneva 14, Switzerland.en_GB
dc.identifier.journalExpert Opinion on Emerging Drugsen_GB
refterms.dateFOA2019-03-04T10:05:47Z


Files in this item

Thumbnail
Name:
Ambisome_Leishmaniasis_EOED_20 ...
Size:
455.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record